Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00193531
Status:
COMPLETED
Last Update Posted:
2023-04-11
First Post:
2005-09-12
Brief Title:
Paclitaxel Carboplatin and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Sponsor:
SCRI Development Innovations LLC
Organization:
SCRI Development Innovations LLC
Study Overview
Official Title:
Phase II Study of Paclitaxel Carboplatin and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
carboplatin and etoposide followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas We hope to identify a standard treatment for this unusual group of patients who are not usually eligible for clinical trials
Detailed Description:
Upon determination of eligibility patients will be receive
Paclitaxel Carboplatin Etoposide
Paclitaxel Carboplatin Etoposide
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None